We’re pleased to today announce that PRISYM ID, a leading provider of regulated content and label management solutions with a focus on clinical trials, medical device, and pharmaceutical labeling has joined the Loftware family.
Throughout 2021 we at PRISYM ID have continued to be dominated by the changes and challenges of the pandemic. As the Holidays approach, I wanted to say a huge thank you to everyone who’s continued to work so hard during the last 12 months to overcome these (now not so unique) set of challenges. In a year that started with further restrictions and a nervousness around implementing a world-wide vaccination program, we finish 2021 attempting to find a new sense of normality. In no other year have I felt such an overwhelming sense of pride to work in a sector that’s shown such incredible resilience, adaptability and courage in the face of such changing times. As the world slowly adjusts to our new reality, it’s been a real privilege to look back and reflect on the key achievements of the last 12 months and how we have overcome the challenges posed by Covid. The pandemic has left a lasting legacy for the life science and med tech industries and, with the expedient and successful vaccine role out, it has fundamentally re-written the rules of what is feasible in terms of speed-to-market for new products and raised expectations considerably. I’m proud to say that PRISYM ID has risen to those expectations. Following our announcement of five significant business wins at the start of the year, PRISYM ID has successfully implemented a further six new regulated labeling software systems as demand from across the medical device and life science sectors increases. This has demonstrated that the industry is recovering from the impact of the pandemic and is refocusing on making investment decisions that will help it prepare for the future. We also showcased our expertise in helping med tech, pharma and clinical research companies negotiate regulatory change; providing resources to help those in the industry successfully prepare for the changes in 2021. When so much was changing around us, I am hugely grateful to existing and new clients for trusting us to support your supply chain and production needs. I look forward to working with you in 2022. Perhaps most important of all, I wanted to express my deep admiration and respect to everyone at PRISYM ID – it’s been an honor to lead this organization through these times. Yet again, you’ve shown extraordinary diligence, passion and expertise in delivering for our clients, and I know that we will continue to great success in 2022. As we break for the festivities, I hope you enjoy a very happy and relaxing holiday and I look forward to welcoming you back in the new year. Wishing you all a very Happy Holiday, Richard
Now more than ever, the clinical trials’ landscape touches more regions than ever before. As a result, new studies are grappling with the challenge of managing variable local language labeling requirements.